Clinical Trials Directory

Trials / Completed

CompletedNCT05806619

Glioma: Biomolecular Aspects

Glioma: BIOMOLECULAR Aspects From Tissue to Radiomics

Status
Completed
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
Regina Elena Cancer Institute · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Main limitations in Glioma studies are due to the wide heterogeneity and genetic instability of the tumor and to the fact that the molecular informations are static, i.e. obtained on the tumor at its onset. Instead, spontaneous or therapy-induced variations are difficult to evaluate and they would need further sampling of the tumor throughout the clinical history. Currently these data are more and more routinely used not only for diagnostics but also in the clinical management of the patient. Furthermore, microenvironment study is becoming increasingly important. It is also important correlate morpho-functional pathway and brain Magnetic Resonance. Therefore, the main goal of the study is to correlate the data obtained with morphological (site, signal intensity, margins, behavior after contrast medium infusion, mismatch between T2 and FLAIR sequences) and non-morphological MR imaging through a radiomic approach and Diffusion and Perfusion study, with molecular data relating to the IDH mutation, MGMT gene promoter methylation, 1p/19q co-deletion and EGFRvIII expression. Furthermore, it is proposed to carry out a correlation between the radiological data and the mutations found in the NGS panel.

Conditions

Interventions

TypeNameDescription
OTHERhistopathological analysis; morphological and non-morphological magnetic resonanceThe surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.

Timeline

Start date
2019-10-22
Primary completion
2022-02-01
Completion
2022-09-30
First posted
2023-04-10
Last updated
2023-04-10

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT05806619. Inclusion in this directory is not an endorsement.